Evolocumab + Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Homozygous Familial Hypercholesterolemia
Conditions
Homozygous Familial Hypercholesterolemia
Trial Timeline
Apr 5, 2012 → Jan 31, 2014
NCT ID
NCT01588496About Evolocumab + Placebo
Evolocumab + Placebo is a phase 2/3 stage product being developed by Amgen for Homozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01588496. Target conditions include Homozygous Familial Hypercholesterolemia.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06081153 | Phase 1 | Recruiting |
| NCT03872401 | Phase 3 | Completed |
| NCT03433755 | Phase 3 | Terminated |
| NCT03515304 | Phase 2 | Completed |
| NCT02833844 | Phase 3 | Completed |
| NCT02729025 | Phase 3 | Completed |
| NCT02392559 | Phase 3 | Completed |
| NCT01813422 | Phase 3 | Completed |
| NCT01764633 | Phase 3 | Completed |
| NCT01763918 | Phase 3 | Completed |
| NCT01588496 | Phase 2/3 | Completed |
| NCT01375751 | Phase 2 | Completed |
| NCT01133522 | Phase 1 | Completed |
Competing Products
20 competing products in Homozygous Familial Hypercholesterolemia